Biosimilars: US Payer Perspectives
Establishing biosimilar interchangeability, patent litigation, negative stakeholder attitudes, poor discounts, and defensive originator strategies have underpinned the sluggish development of the US biosimilar market.
So, what would payers like to see?
Will adalimumab biosimilars and the anticipated launch of biosimilar Stelara in 2025 be the catalysts to drive meaningful healthcare savings? What factors influence payers’ adoption and support of biosimilars?
Companies
AbbVie, Amgen, Novartis, Teva, Pfizer, Boehringer Ingelheim, CVS, Celltrion, Samsung Bioepis, Coherus, Organon, Viatris, Fresenius Kabi, Cost Plus Drugs
- Subject synopsis
- Research methodology and objectives
- Methodology
- Objectives
- Key insights summary
- Issues and insights
- Recent changes in the US biosimilars market
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Strategic switching to biosimilars
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook